Sleep medicine experts from the Mount Sinai Health System are presenting new research at SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies running until June 7 in Indianapolis.
Most patients with Alzheimer’s disease or other types of dementia will not be eligible for the new disease modifying drugs approved by the FDA for mild cognitive impairment or mild dementia. But an op-ed co-written by UCLA’s Dr. David Reuben,…
According to the newly released “Alzheimer’s Disease Drug Development Pipeline: 2023,” there are currently 187 clinical trials in the Alzheimer’s drug development pipeline – the most ever on record. This momentum is driven in part by greater investment from the pharma industry and a bump in biologic therapies – particularly monoclonal antibodies – that were central to the success of both recent FDA-approved drugs.
The annual report spots trends in clinical trial design and outcome measures, and also investigate the types of agents and biological targets that are being pursued.
The anti-dementia medication lecanemab and its ancillary costs could add $2 billion to $5 billion in annual Medicare spending if the Centers for Medicare and Medicaid Services (CMS) revise their coverage decision. Currently, the medication is covered only for patients who are enrolled in clinical trials.
Following a Mediterranean-based ketogenic diet may decrease the risk of Alzheimer’s disease, according to a new study from scientists at Wake Forest University School of Medicine.
Living closer to outdoor spaces and water sources may reduce older people’s risk of having serious psychological distress, which can lead to mild cognitive impairment and dementia, according to a preliminary study released today, February 22, 2023, that will be presented at the American Academy of Neurology’s 75th Annual Meeting being held in person in Boston and live online from April 22-27, 2023.
The presence of apathy in patients with mild cognitive impairment is strongly linked to a progression to Alzheimer’s disease, giving physicians a possible early diagnosis tool, according to UTHealth Houston research published recently in the Journal of Alzheimer’s Disease.
Experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available for interviews and to comment on research being presented at the conference.
A new study compares two approaches to improving memory in people with mild cognitive impairment.
Despite the absence of a curative drug, improvements in MCI may be possible though use of substances and tactics published throughout medical journals and summarized here.
UC San Diego researchers have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer’s disease or Mild Cognitive Impairment, a condition that often precedes full-blown dementia.
As yet there is no prescription drug to cure mild cognitive impairment (MCI), often a harbinger of Alzheimer’s disease. Medical research journals reveal curcumin can sometimes bolster cognition. It merits a try.
Although cardiologists often decry coconut oil because of certain fats it contains, they overlook the growing evidence that other fatty constituents, especially medium-chain triglycerides, may alleviate some cases of mild cognitive impairment and Alzheimer’s disease
Mild cognitive impairment affects millions of seniors. There is no curative drug. Seven possibly helpful supplements gleaned from medical journal articles are described
Biogen tried, and failed, to win FDA committee approval for its anti-amyloid Alzheimer’s drug. The Alzheimer’s Association supported the application but did not reveal significant monies received from the firm.
MCI911.com had added a new department, Research Radar, to focus exclusively on advancements to aid fighting MCI
Battling the mild cognitive impairment stage of Alzheimer’s may disease may “nip it in the bud”.
Patients with mild cognitive impairment can aggressively utilize currently available substances and practices to try and delay their brain degeneration
UC San Diego researchers report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer’s disease.
Using sex-specific scores on memory tests may change the diagnosis for 20 percent of those currently diagnosed with mild cognitive impairment (MCI), with possibly more women and fewer men being diagnosed with MCI, according to a new study published online in the journal Neurology.